Asano M, Sekikawa A, Kim H, et al. - In this study, the safety and pharmacokinetics of cotadutide, a dual glucagon-like peptide-1, and glucagon receptor agonist, in overweight Asian participants with or without type 2 diabetes (T2D) was explored. Researchers designed a phase 1, randomized, blinded, single-ascending dose study, including 24 Japanese and eight Chinese healthy adults (body mass index] 23-40 kg/m2) who received one subcutaneous dose of cotadutide (50-150 or 100 μg, respectively) or placebo. According to the findings, once-daily cotadutide was found to be effective and well-tolerated up to 300 μg in overweight Japanese patients with T2D. There is a need for future assessment in Asian populations.